logo

For the Inventor, By the Inventor

Marburg, Germany

Csl Behring Gmbh


USPTO Granted Patents = 74

% Expired Patents = 29.7



Trademarks = 114

Forward Citations = 425

Loading Chart...
Loading Chart...

121 inventors (with patents filed for the assignee):

goldMedal Stefan Schulte (17 out of 30 patents)

silverMedal Marc Nolte (13 out of 24 patents)

bronzeMedal Thomas Weimer (13 out of 28 patents)

4.  Hubert Metzner (11 out of 28 patents)

5.  Gerhard Dickneite (8 out of 29 patents)

6.  Scott M Kee (7 out of 7 patents)

7.  Paul I Cook (7 out of 8 patents)

8.  James R Smith (7 out of 7 patents)

9.  Robert Kling (7 out of 7 patents)

10.  Scott A Fowler (7 out of 9 patents)

11.  David A Weber (7 out of 34 patents)

12.  Hans-Arnold Stoehr (7 out of 12 patents)

13.  Wiegand Lang (7 out of 11 patents)

14.  Annette Feussner (7 out of 18 patents)

15.  Stefan Schmidbauer (6 out of 7 patents)


Core Competencies:
Factor XII Inhibitors
Alpha-1-Antitrypsin
Hemophilia Treatments
Blood Coagulation
Immunoglobulin
C1-Inhibitor
Ischemia-Reperfusion Injury
Therapeutic Proteins
Fibrin Adhesive Granulate
Von Willebrand Factor
Coagulation Factor X
Monoclonal Antibodies

74 patents:

1. D1070201 - Wash carriage rack (2025-04-08),
2. 12065481 - Therapy using a factor XII inhibitor in a neurotraumatic disorder (2024-08-20),
3. 11857610 - Methods for reducing risk of onset of acute graft versus host disease after hematopoietic cell transplantation (2024-01-02),
4. 11744880 - Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings (2023-09-05),
5. 11554156 - Pharmaceutical formulations of C1 esterase inhibitor (2023-01-17),
6. 11426680 - Hydrophobic charge induction chromatographic protein depleted solution (2022-08-30),
7. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),
8. 11224643 - Methods of treatment using alpha-1-antitrypsin compositions (2022-01-18),
9. 10973891 - Treatment and prevention of remote ischemia-reperfusion injury (2021-04-13),
10. 10513560 - Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (2019-12-24),
11. 10471142 - Combination therapy using immunoglobulin and C1-Inhibitor (2019-11-12),
12. 10441631 - Therapeutic agent for amniotic fluid embolism (2019-10-15),
13. 10335467 - Methods of treatment using alpha-1-antitrypsin compositions (2019-07-02),
14. 10286047 - Treatment and prevention of remote ischemia-reperfusion injury (2019-05-14),
15. 10232015 - Sugar compositions for treating hemophilia A and/or Von Willebrand disease (2019-03-19),
Company Overview
Csl Behring Gmbh, headquartered in Marburg, Germany, specializes in the development and manufacturing of innovative therapies for patients with serious and rare conditions. The company focuses on blood coagulation, particularly in areas such as hemophilia treatments and factor XII inhibitors. Csl Behring is also engaged in research related to alpha-1-antitrypsin, immunoglobulin therapies, and C1-inhibitors, addressing critical health challenges including ischemia-reperfusion injury and the production of therapeutic proteins.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Csl Behring Gmbh USPTO Patent Assignee Logo
74 Patents

#4 in Marburg

#777 in Germany

#10,131 in the World

Marburg, DE
Marburg, Germany

Csl Behring Gmbh

Forward Citations = 425

121 inventors:

goldMedal Stefan Schulte (17 out of 30 patents)

silverMedal Marc Nolte (13 out of 24 patents)

bronzeMedal Thomas Weimer (13 out of 28 patents)

4.  Hubert Metzner (11 out of 28 patents)

5.  Gerhard Dickneite (8 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Csl Behring Gmbh. Retrieved from https://idiyas.com/company/csl-behring

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…